Why the study?
Does the extent of histologic necrosis after neoadjuvant chemotherapy predict local recurrence and overall survival in patients with soft tissue sarcomas of the extremities?
Population
82 patients who received neoadjuvant chemotherapy for treatment of soft tissue sarcomas of the extremities
Comparison
Histologic necrosis ≥95% following neoadjuvant… vs Histologic necrosis <95% following neoadjuvant…
Design
Cohort
Follow-up
average 65 months (range, 24-154 months)
Authors
Loading...
Necrosis extent should not inform prognosis in extremity soft tissue sarcoma; challenges its validity as a surrogate endpoint.
Does the extent of histologic necrosis after neoadjuvant chemotherapy predict local recurrence and overall survival in patients with soft tissue sarcomas of the extremities?
The amount of histologic tissue necrosis following neoadjuvant chemotherapy does not predict local recurrence or overall survival in patients with soft tissue sarcomas of the extremities.
Menendez et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: